Antiretrovirals

New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor

Antiretrovirals, Capsid inhibitors, Clinical Data, Clinical Trials, Gilead, HIV infections, Multi-drug resistant HIV-1 infection, R&D

Gilead Sciences Inc. announced new results from the Phase 2/3 CAPELLA trial evaluating lenacapavir, the company’s investigational, long-acting HIV-1 capsid inhibitor, in heavily treatment-experienced people living with multi-drug resistant HIV.

FDA approves ViiV’s Cabenuva as first complete long-acting regimen for HIV treatment

Adults, Antiretrovirals, Approvals, Clinical Trials, FDA, First-In-Class, GlaxoSmithKline, HIV-1, New Drug Applications, Patient Assistance Programs, R&D, Therapeutics

The U.S. Food and Drug Administration approved ViiV Healthcare’s Cabenuva as the only complete long-acting regimen for the treatment of HIV-1 infection in adults.

As Death Toll Climbs, WHO Finds No Benefit with 4 Top Covid-19 Treatments

Antiretrovirals, Biopharma Companies, Clinical Trials, Coronavirus Disease (COVID-19) Pandemic, Hospitalized COVID-19 Patients, Hydroxychloroquine, Interferon-beta-1a, Lopinavir, Mortality Rates, New England Journal of Medicine, R&D, Remdesivir, World Health Organization

Once touted as promising treatments and by some even a cure, the World Health Organization dashes those claims, finding no benefit in the use of four popular Covid-19 treatments (remdesivir, hydroxychloroquine, lopinavir, or interferon-beta-1a) on hospitalized patients.